Pharma & Biotech Global Week in Review 27 April 2011 from IP Think Tank

Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Highlights this week included:

Pfizer starts R&D in China after IPR in China challenges (IP Dragon)

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

General

WHO pandemic Flu deal doesn’t go far enough, NGOs say (IP Watch)

Strategies for R&D in emerging economies (ipmINDs)

Top 5 drug patent expirations in 2011 (Patent Quality Matters)

Plant Breeder’s Rights – A blessing or a curse? (IP Watch)

China: Pfizer starts R&D in China after IPR in China challenges (IP Dragon)

UK: IPO inviting comment on C-630/10 University of Queensland, CSL Ltd v Comptroller-General of Patents, Designs and Trade Marks and C-130/11 Neurim v Comptroller General of Patents (The SPC Blog) (The SPC Blog)

US: New generics quickly grab 80% of sales volume (GenericsWeb)

Products

Actos (Pioglitazone) – US: Takeda agrees to dismiss one Actos infringement suit against Apotex (Patent Docs)

Angiomax (Bivalirudin) – US: Amendment to the America Invents Act would give MDCO some legislative security in battle over Angiomax PTE (FDA Law Blog)

Antara (Fenofibrate) – Global: Lupin in licence pact with Abbott on cholesterol drug (GenericsWeb)

Arzerra (Ofatumumab) / Benlysta (Belimumab) – US: Genentech files patent infringement suit against Glaxo and others based on their Arzerra and Benlysta products (Patent Docs)

Cambia (Diclofenac) – US: Nautilus Neurosciences files patent infringement suit against Wockhardt in response to Para IV challenge (Patent Docs)

Dexilant (Dexlansoprazole) – US: Takeda files patent infringement suit against Impax in response to Para IV challenge (Patent Docs)

Effexor (Venlafaxine) – US: Wyeth and Orchid enter licensing agreement in Effexor XR suit (Patent Docs)

Focalin (Dexmethylphenidate) – US: Celegene, Novartis file patent infringement suit against Mylan in response to Para IV certification filing (Patent Docs)

Lipitor (Atorvastatin) – US: District Court set to decide whether Ranbaxy forfeited 180-day exclusivity on generic Lipitor (Orange Book Blog)

Losartan HCTZ – France: Another SPC coming – The Return (Kluwer Patent Blog)

Myfortic (Mycophenolic acid) – US: Novartis sues Teva to block generic drug (GenericsWeb)

OxyContin (Oxycodone) – US: Purdue files separate patent infringement suits against Ranbaxy and Impax in response to Para IV certification filings (Patent Docs) (GenericsWeb)

Treximet (Sumatriptan, Naproxen) – US: Pozen secures injunction blocking Par’s generic Treximet (Patent Docs)

Vimovo (Naproxen, Esomeprazole magnesium) – US: AstraZeneca and Pozen file patent infringement lawsuit against Dr. Reddy’s (GenericsWeb)

Zyprexa (Olanzapine) – Spain: Ranbaxy launches generic Olanzapine tablets, in Spain, on day-1 following patent expiry (GenericsWeb)

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: